Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.

[1]  S. Schneeweiss,et al.  Repeated hospitalizations predict mortality in the community population with heart failure. , 2007, American heart journal.

[2]  S. Kazi,et al.  The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists , 2007, Rheumatology International.

[3]  S. Gabriel,et al.  Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[4]  J. Lima,et al.  Epidemiology of congestive heart failure: general considerations , 2005 .

[5]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[6]  M. Hudson,et al.  Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. , 2005, Rheumatology.

[7]  Peter C Austin,et al.  Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research , 2005, Medical care.

[8]  S. Gabriel,et al.  The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. , 2005, Arthritis and rheumatism.

[9]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[10]  F. Wolfe,et al.  Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.

[11]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[12]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[13]  Paul Grootendorst,et al.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[14]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[15]  B H McFarland,et al.  The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience. , 2000, Journal of clinical epidemiology.

[16]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[17]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[18]  T. LeJemtel,et al.  Pathophysiological Correlates of Increased Serum Tumor Necrosis Factor in Patients With Congestive Heart Failure: Relation to Nitric Oxide‐Dependent Vasodilation in the Forearm Circulation , 1994, Circulation.

[19]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.